Pernas, Sonia <br/><br/>
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.  [electronic resource] 

 -  The Lancet. Oncology  06 2018 
 - 812-824 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(18)30147-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Biomarkers, Tumor--analysis<br/>Breast Neoplasms--chemistry<br/>Female<br/>Furans--administration & dosage<br/>Humans<br/>Ketones--administration & dosage<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Peptides, Cyclic--administration & dosage<br/>Receptor, ErbB-2--analysis<br/>Receptors, CXCR4--antagonists & inhibitors<br/>Spain<br/>Time Factors<br/>Treatment Outcome<br/>United States